GSK PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,776 GBX | +0.07% |
|
-1.92% | +22.41% |
| 05-17 | UK's FTSE 100 Closes Lower Amid Inflation Focus | MT |
| 05-17 | Marti Technologies Hires Oguz Erkan as CFO | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 31.63B 40.15B 54.69B | Sales 2025 * | 33.58B 42.63B 58.07B | Capitalization | 72.39B 91.89B 125B |
|---|---|---|---|---|---|
| Net income 2024 * | 5.54B 7.04B 9.59B | Net income 2025 * | 6.49B 8.24B 11.23B | EV / Sales 2024 * | 2.68 x |
| Net Debt 2024 * | 12.29B 15.6B 21.25B | Net Debt 2025 * | 9.07B 11.51B 15.68B | EV / Sales 2025 * | 2.43 x |
| P/E ratio 2024 * |
12.9
x | P/E ratio 2025 * |
11.1
x | Employees | 70,212 |
| Yield 2024 * |
3.43% | Yield 2025 * |
3.56% | Free-Float | 94.54% |
More Fundamentals
* Assessed data
More news
Latest transcript on GSK plc
More press releases
| 1 day | +0.07% | ||
| 1 week | -1.92% | ||
| Current month | +6.11% | ||
| 1 month | +8.28% | ||
| 3 months | +5.81% | ||
| 6 months | +26.08% | ||
| Current year | +22.41% |
1 week
1 764.50
1 823.50
1 month
1 610.501 823.50
Current year
1 453.201 823.50
1 year
1 302.601 823.50
3 years
1 280.923 408.16
5 years
1 280.923 408.16
10 years
1 280.923 408.16
| Managers | Title | Age | Since |
|---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
James Ford
CMP | Compliance Officer | - | 95-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Jonathan Symonds
CHM | Chairman | 66 | 19-08-31 |
Hal Barron
BRD | Director/Board Member | 62 | 17-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.17% | 11 M€ | +0.83% | - | |
| 3.15% | 17 M€ | +8.10% | - | |
| 2.51% | 7 M€ | +9.05% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 1,775 | +0.01% | 713 713 |
| 24-05-17 | 1,775 | -0.48% | 9,685,470 |
| 24-05-16 | 1,784 | -1.60% | 5,275,162 |
| 24-05-15 | 1,812 | +0.14% | 4,861,330 |
| 24-05-14 | 1,810 | 0.00% | 4,739,267 |
Delayed Quote London S.E., May 20, 2024 at 07:58 am
More quotes
GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
Sector
Pharmaceuticals
Calendar
2024-05-19
- Barclays European Select Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
17.75
GBP
Average target price
20.32
GBP
Spread / Average Target
+14.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +22.41% | 91.97B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +13.84% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- GSK Stock
